sulpiride has been researched along with Basal Ganglia Diseases in 33 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review the pharmacology, pharmacokinetics, clinical investigations, and adverse effects of sulpiride as a treatment for schizophrenia." | 4.79 | Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. ( Caley, CF; Weber, SS, 1995) |
| "Compared to traditional neuroleptics, most of the new antipsychotics are characterized by a low extrapyramidal side effect (EPS) liability and varying antipsychotic efficacy." | 3.77 | New antipsychotics: classification, efficacy, and adverse effects. ( Gerlach, J, 1991) |
| " They underwent a series of psychomotor and cognitive tests 1 hour before and 3 and 6 hours after dosing on days 1 and 5." | 2.69 | Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. ( de Bie, A; Louwerens, JW; Milius, H; Muntjewerff, ND; O'Hanlon, JF; Patat, A; Ramaekers, JG; Rosenzweig, P, 1999) |
| " Adverse effects include acute dyskinesia or Parkinsonism, which may occur after many months of treatment." | 2.43 | The safety of veralipride. ( De Leo, V; Delia, A; Faldini, E; Morgante, G; Musacchio, MC; Petraglia, F, 2006) |
| " Safety data collection was performed using open reporting, UKU scales or specific extrapyramidal side-effect scales; electrocardiogram recording and vital signs examination; laboratory data collection." | 2.40 | Safety of amisulpride (Solian): a review of 11 clinical studies. ( Coulouvrat, C; Dondey-Nouvel, L, 1999) |
| " Model predictions were used to simulate dose-response and dose-EPS." | 1.46 | A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease. ( Bertrand, J; Brownings, S; D'Antonio, F; Dunn, JT; Greaves, S; Howard, R; Kessler, R; Marsden, P; McLachlan, E; Nair, A; Reeves, S; Smith, A; Taylor, D; Uchida, H, 2017) |
| " Adverse effects were acute dyskinesia (n=2) or parkinsonian syndrome, which occurred after several months or years of treatment (n=15)." | 1.33 | [Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases]. ( Andréjak, M; Geslin, JM; Gras-Champel, V; Lemaire-Hurtel, AS; Masmoudi, K; Masson, H; Munier, A, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (30.30) | 18.7374 |
| 1990's | 8 (24.24) | 18.2507 |
| 2000's | 13 (39.39) | 29.6817 |
| 2010's | 2 (6.06) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Reeves, S | 1 |
| Bertrand, J | 1 |
| McLachlan, E | 1 |
| D'Antonio, F | 1 |
| Brownings, S | 1 |
| Nair, A | 1 |
| Greaves, S | 1 |
| Smith, A | 1 |
| Dunn, JT | 1 |
| Marsden, P | 1 |
| Kessler, R | 1 |
| Uchida, H | 1 |
| Taylor, D | 2 |
| Howard, R | 1 |
| Sparshatt, A | 1 |
| Patel, MX | 1 |
| Kapur, S | 1 |
| Rizos, E | 1 |
| Douzenis, A | 1 |
| Gournellis, R | 1 |
| Christodoulou, C | 1 |
| Lykouras, LP | 1 |
| Molina, JD | 1 |
| Toledo-Romero, F | 1 |
| López-Rodríguez, E | 1 |
| Amorin-Díaz, M | 1 |
| Lerma-Carrillo, I | 1 |
| López-Muñoz, F | 1 |
| Pani, L | 1 |
| Lecrubier, Y | 3 |
| Lambert, TJ | 1 |
| Castle, DJ | 1 |
| Kotler, M | 1 |
| Strous, RD | 1 |
| Reznik, I | 1 |
| Shwartz, S | 1 |
| Weizman, A | 1 |
| Spivak, B | 1 |
| Jagadheesan, K | 1 |
| Muirhead, D | 1 |
| Masmoudi, K | 1 |
| Gras-Champel, V | 1 |
| Lemaire-Hurtel, AS | 1 |
| Masson, H | 1 |
| Munier, A | 1 |
| Geslin, JM | 1 |
| Andréjak, M | 1 |
| De Leo, V | 1 |
| Morgante, G | 1 |
| Musacchio, MC | 1 |
| Faldini, E | 1 |
| Delia, A | 1 |
| Petraglia, F | 1 |
| Quintin, P | 1 |
| Bouhassira, M | 1 |
| Perrin, E | 1 |
| Lancrenon, S | 1 |
| Limosin, F | 1 |
| Mann, K | 1 |
| Bartels, M | 1 |
| Bauer, H | 1 |
| Gaertner, HJ | 2 |
| Alfredsson, G | 1 |
| Härnryd, C | 1 |
| Wiesel, FA | 1 |
| Schwartz, M | 1 |
| Weller, B | 1 |
| Erdreich, M | 1 |
| Sharf, B | 1 |
| Caley, CF | 1 |
| Weber, SS | 1 |
| Strange, PG | 1 |
| Ramaekers, JG | 1 |
| Louwerens, JW | 1 |
| Muntjewerff, ND | 1 |
| Milius, H | 1 |
| de Bie, A | 1 |
| Rosenzweig, P | 1 |
| Patat, A | 1 |
| O'Hanlon, JF | 1 |
| Kamijo, Y | 1 |
| Soma, K | 1 |
| Fukuda, M | 1 |
| Asari, Y | 1 |
| Ohwada, T | 1 |
| Coulouvrat, C | 1 |
| Dondey-Nouvel, L | 1 |
| Möller, HJ | 1 |
| Petit, H | 1 |
| De Maio, D | 1 |
| Caponeri, MA | 1 |
| Cicchetti, V | 1 |
| Mellado, C | 1 |
| Scieghi, G | 1 |
| Caroli, F | 1 |
| Littre-Poirier, MF | 1 |
| Ginestet, D | 1 |
| Deniker, P | 1 |
| Maurel, H | 1 |
| Pujol, B | 1 |
| Gerlach, J | 1 |
| Delcker, A | 1 |
| Schoon, ML | 1 |
| Oczkowski, B | 1 |
| Lee, SA | 1 |
| Kim, JS | 1 |
| Ahn, JH | 1 |
| Choi, KG | 1 |
| Chouza, C | 1 |
| Caamano, JL | 1 |
| Romero, S | 1 |
| Lorenzo, J | 1 |
| Feres, S | 1 |
| Horikawa, H | 1 |
| Konagaya, M | 1 |
| Mano, Y | 1 |
| Takayanagi, T | 1 |
| Haase, HJ | 1 |
| Floru, L | 1 |
| Ulrich, F | 1 |
10 reviews available for sulpiride and Basal Ganglia Diseases
| Article | Year |
|---|---|
Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Drug Monitoring | 2009 |
Clinical implications of dopamine research in schizophrenia.
Topics: Amisulpride; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Receptors, Dopamine; Res | 2002 |
Amisulpride: progress and outcomes.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Quality of Life; Receptors, Dopam | 2002 |
Pharmacological approaches to the management of schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dibenzothiaze | 2003 |
The safety of veralipride.
Topics: Adult; Aged; Basal Ganglia Diseases; Dopamine D2 Receptor Antagonists; Estrogens; Female; Half-Life; | 2006 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; | 2006 |
Sulpiride: an antipsychotic with selective dopaminergic antagonist properties.
Topics: Animals; Autonomic Nervous System Diseases; Basal Ganglia Diseases; Clinical Trials as Topic; Double | 1995 |
Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
Topics: Basal Ganglia; Basal Ganglia Diseases; Brain; Clozapine; Dopamine Agents; Dopamine D2 Receptor Antag | 1993 |
Safety of amisulpride (Solian): a review of 11 clinical studies.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Blood Cell Count | 1999 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors | 1991 |
11 trials available for sulpiride and Basal Ganglia Diseases
| Article | Year |
|---|---|
Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.
Topics: Adolescent; Adult; Affect; Antipsychotic Agents; Anxiety; Basal Ganglia Diseases; Benzodiazepines; C | 2004 |
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
Topics: Adult; Affect; Amisulpride; Antipsychotic Agents; Attention; Basal Ganglia Diseases; Benzodiazepines | 2006 |
Amisulpride--an open clinical study of a new benzamide in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as Topic; Electroe | 1984 |
Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients--relationship to drug concentrations.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Chlorpromazine; Depression; Female; Humans; Male; Schizop | 1984 |
Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic.
Topics: Adult; Affective Disorders, Psychotic; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Co | 1999 |
Amisulpride: efficacy in the management of chronic patients with predominant negative symptoms of schizophrenia.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; | 2001 |
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph | 1975 |
[Situation of sultopride among present-day neuroleptics].
Topics: Anxiety; Asthenia; Basal Ganglia Diseases; Benzamides; Bipolar Disorder; Clinical Trials as Topic; D | 1975 |
New antipsychotics: classification, efficacy, and adverse effects.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzamides; Humans; Isoxazoles; Piperidines; Receptors | 1991 |
Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Double-Blind Method; Female; Halop | 1990 |
[Clinical-neuroleptic investigation of N-((1-ethyl-pyrrolidine-2-yl)-methyl)-2-methoxy-5-sulfamyl-benzamide-neuroleptic sulpiride (Dogmatil) in acutly ill schizophrenics].
Topics: Adolescent; Adult; Aged; Basal Ganglia Diseases; Biperiden; Blood Pressure; Clinical Trials as Topic | 1974 |
13 other studies available for sulpiride and Basal Ganglia Diseases
| Article | Year |
|---|---|
A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amisulpride; Basal Ganglia Diseases; Brain; Delusions; D | 2017 |
Tardive dyskinesia in a patient treated with quetiapine.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dibenzothiazepines; Dyskine | 2009 |
Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Diagn | 2011 |
Improvement of amisulpride-induced extrapyramidal symptoms with quetiapine.
Topics: Aged; Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Dibenzothiazepines; Humans; Male; M | 2004 |
[Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases].
Topics: Aged; Akathisia, Drug-Induced; Basal Ganglia Diseases; Dopamine Antagonists; Female; Humans; Male; M | 2005 |
Rabbit syndrome and tardive dyskinesia: two complications of chronic neuroleptic treatment.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Diagnosis, Differential; Dyskinesia, Drug-Induced; Fem | 1995 |
Rabbit syndrome following phenol ingestion.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Drug Interactions; Female; Humans; Phenol; Suici | 1999 |
Is amisulpride an 'atypical' atypical antipsychotic agent?
Topics: Amisulpride; Antipsychotic Agents; Basal Ganglia Diseases; Humans; Limbic System; Receptors, Dopamin | 2000 |
[Sulpiride and tiapride in neurology. Introductory report].
Topics: Basal Ganglia Diseases; Benzamides; Chorea; Dyskinesia, Drug-Induced; Humans; Sulpiride; Tiapamil Hy | 1979 |
Sulpiride and extrapyramidal syndromes in chronic heroin addiction.
Topics: Animals; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Heroin Dependence; Humans; Rats; Sulpiri | 1978 |
Sulpiride in Meige's syndrome: possible role of glutamate.
Topics: Adult; Aged; Basal Ganglia Diseases; Corpus Striatum; Dopamine; Female; Glutamates; Glutamic Acid; H | 1988 |
Extrapyramidal effects of benzamides.
Topics: Basal Ganglia Diseases; Benzamides; Dyskinesia, Drug-Induced; Humans; Metoclopramide; Movement Disor | 1985 |
[Three cases of lingual ballistic movement followed by a rigid-dystonic state of the tongue].
Topics: Aged; Basal Ganglia Diseases; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Male; Movement | 1985 |